Henry Schein’s (HSIC) Outperform Rating Reiterated at Barrington Research

Barrington Research reissued their outperform rating on shares of Henry Schein (NASDAQ:HSIC) in a research report released on Wednesday,Benzinga reports. Barrington Research currently has a $82.00 price target on the stock. Barrington Research also issued estimates for Henry Schein’s Q4 2024 earnings at $1.20 EPS, FY2024 earnings at $4.75 EPS, Q1 2025 earnings at $1.12 EPS, Q2 2025 earnings at $1.26 EPS, Q3 2025 earnings at $1.27 EPS, Q4 2025 earnings at $1.46 EPS, FY2025 earnings at $5.12 EPS and FY2026 earnings at $5.80 EPS.

A number of other equities analysts have also recently issued reports on HSIC. StockNews.com cut shares of Henry Schein from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. Baird R W upgraded Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. Evercore ISI increased their target price on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 8th. JPMorgan Chase & Co. reduced their price target on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Finally, Robert W. Baird dropped their price objective on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Henry Schein currently has an average rating of “Hold” and an average price target of $77.50.

Henry Schein Stock Down 2.1 %

Shares of NASDAQ HSIC traded down $1.43 during trading on Wednesday, reaching $68.00. 871,840 shares of the stock were exchanged, compared to its average volume of 1,518,488. The business’s 50-day moving average price is $70.51 and its 200 day moving average price is $69.75. The company has a market capitalization of $8.48 billion, a price-to-earnings ratio of 27.98, a price-to-earnings-growth ratio of 2.00 and a beta of 0.87. Henry Schein has a twelve month low of $62.12 and a twelve month high of $82.63. The company has a quick ratio of 0.90, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.24 billion. During the same quarter last year, the firm earned $1.32 EPS. Henry Schein’s quarterly revenue was up .4% on a year-over-year basis. As a group, equities analysts forecast that Henry Schein will post 4.76 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the transaction, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.14% of the company’s stock.

Institutional Trading of Henry Schein

Institutional investors have recently modified their holdings of the company. UniSuper Management Pty Ltd boosted its stake in shares of Henry Schein by 611.8% in the 1st quarter. UniSuper Management Pty Ltd now owns 13,695 shares of the company’s stock valued at $1,034,000 after purchasing an additional 11,771 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Henry Schein by 64.2% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 41,558 shares of the company’s stock valued at $3,138,000 after buying an additional 16,241 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new stake in Henry Schein during the second quarter worth about $46,683,000. Nordea Investment Management AB raised its stake in shares of Henry Schein by 8.9% in the first quarter. Nordea Investment Management AB now owns 9,785 shares of the company’s stock valued at $744,000 after acquiring an additional 798 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Henry Schein by 1.7% in the first quarter. Vanguard Group Inc. now owns 15,432,001 shares of the company’s stock valued at $1,165,425,000 after acquiring an additional 260,537 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.